[October 06, 2015]

Research and Markets: Global Smallpox Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/99vwtr/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued prjects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Bavarian Nordic A/S
• CEL-SCI Corporation
• Chimerix, Inc.
• EpiVax, Inc.
• Nanotherapeutics, Inc.
• Oncovir, Inc.
• SIGA Technologies, Inc.
• Symphogen A/S
• TapImmune Inc.
• Tonix Pharmaceuticals Holding Corp.

Drug Profiles

• 24a
• brincidofovir
• CEL-1000
• cidofovir
• imatinib mesylate
• Monoclonal Antibodies for Infectious Disease
• PL-801
• Poly-ICLC
• Sym-002
• tecovirimat
• TPIV-300
• VIR-002

For more information visit http://www.researchandmarkets.com/research/99vwtr/smallpox

View source version on businesswire.com: http://www.businesswire.com/news/home/20151006006690/en/

[ Back To TMCnet.com's Homepage ]